Pages that link to "Q27477742"

The following pages link to Adherence and drug resistance: predictions for therapy outcome (Q27477742):

Displaying 48 items.

• Modeling antiretroviral drug responses for HIV-1 infected patients using differential equation models (Q27015861) (← links)
• Optimal timing and duration of induction therapy for HIV-1 infection (Q28469250) (← links)
• Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection (Q28545971) (← links)
• Early HAART Initiation May Not Reduce Actual Reproduction Number and Prevalence of MSM Infection: Perspectives from Coupled within- and between-Host Modelling Studies of Chinese MSM Populations (Q28550445) (← links)
• Non-linear dynamics models characterizing long-term virological data from AIDS clinical trials (Q30682893) (← links)
• Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration (Q30685690) (← links)
• Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling (Q30892194) (← links)
• Reconciling conflicting clinical studies of antioxidant supplementation as HIV therapy: a mathematical approach (Q33516173) (← links)
• Modelling imperfect adherence to HIV induction therapy (Q33523201) (← links)
• A Bayesian Approach in Differential Equation Dynamic Models Incorporating Clinical Factors and Covariates (Q33824478) (← links)
• Accounting for noncompliance in pharmacoeconomic evaluations (Q34481350) (← links)
• A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns (Q34573789) (← links)
• Compliance with once-daily versus twice or thrice-daily administration of antibiotic regimens: a meta-analysis of randomized controlled trials (Q34822693) (← links)
• Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach. (Q35422530) (← links)
• HIV therapy: managing resistance (Q36104156) (← links)
• Antiretroviral dynamics determines HIV evolution and predicts therapy outcome (Q36374300) (← links)
• Modeling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibility (Q36492224) (← links)
• Exploring ART intake scenes in a human rights-based intervention to improve adherence: a randomized controlled trial (Q36542552) (← links)
• Measuring health-related stigma--a literature review (Q36665809) (← links)
• Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor (Q36675928) (← links)
• Modeling HIV persistence, the latent reservoir, and viral blips (Q37365718) (← links)
• Threshold virus dynamics with impulsive antiretroviral drug effects (Q37458961) (← links)
• Economic impact of poor compliance with pharmaceuticals (Q37609268) (← links)
• Population biological principles of drug-resistance evolution in infectious diseases (Q37849394) (← links)
• Maximum equilibrium prevalence of mosquito-borne microparasite infections in humans (Q38871901) (← links)
• Barriers and facilitators to patients' adherence to antiretroviral treatment in Zambia: a qualitative study. (Q39428773) (← links)
• A comparative analysis of the relative efficacy of vector-control strategies against dengue fever (Q40214733) (← links)
• Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling (Q40246920) (← links)
• The expected and unexpected benefits of dispensing the exact number of pills (Q41677512) (← links)
• Survival of people living with HIV after treatment with traditional Chinese medicine in Henan province of China: a retrospective cohort study (Q41756127) (← links)
• Assessing the impact of adherence to anti-retroviral therapy on treatment failure and resistance evolution in HIV. (Q41760696) (← links)
• The role of family caregivers in HIV medication adherence (Q42690963) (← links)
• Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients (Q43260037) (← links)
• Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity (Q44495120) (← links)
• Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine (Q45090413) (← links)
• Pulse HIV vaccination: feasibility for virus eradication and optimal vaccination schedule (Q45351952) (← links)
• A probabilistic approach for the evaluation of pharmacological effect induced by patient irregular drug intake (Q46175592) (← links)
• Life cycle synchronization is a viral drug resistance mechanism (Q49980878) (← links)
• Modelling the effects of adherence to the HIV fusion inhibitor enfuvirtide (Q51652043) (← links)
• Costs versus benefits: best possible and best practical treatment regimens for HIV. (Q51925691) (← links)
• Dynamics of recurrent viral infection. (Q51935630) (← links)
• Improving estimates of the basic reproductive ratio: using both the mean and the dispersal of transition times. (Q51941219) (← links)
• Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges? (Q51946107) (← links)
• Immune responses and the emergence of drug-resistant virus strains in vivo. (Q51992080) (← links)
• Insight into treatment of HIV infection from viral dynamics models (Q58788145) (← links)
• Bioinformatics-assisted anti-HIV therapy (Q80277830) (← links)
• Modelling the HIV persistence through the network of lymphocyte recirculation in vivo (Q89178727) (← links)
• Self-Reported Long-Term Antiretroviral Adherence: A Longitudinal Study Among HIV Infected Pregnant Women in Mpumalanga, South Africa (Q92950474) (← links)